Morphological aspects of apoptosis in heart diseases

Genzou Takemura, Hisayoshi Fujiwara *

Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan

Received: February 3, 2006; Accepted: February 21, 2006

Abstract

It has been suggested that apoptosis may be responsible for a significant amount of cardiomyocyte death during acute myocardial infarction as well as for a progressive loss of surviving cells in failing hearts. Typical apoptosis can indeed be induced in cardiomyocytes at the experimental conditions. In actual heart diseases, in contrast, there is very little direct morphological evidence of apoptosis in cardiomyocytes occurring at any stage of myocardial infarction and heart failure, despite the availability of much indirect evidence that includes detection of DNA fragmentation and apoptosis-related factors. For that reason, the potential efficacy of therapeutic intervention to prevent apoptosis remains controversial. This review will survey available data from both animals and humans to critically assess the role of cardiomyocyte apoptosis during myocardial infarction and its relevance to myocardial remodeling and during progression to heart failure. Also considered will be nonmyocyte interstitial cells, which have received less attention than myocytes despite definitive evidence of their apoptosis in the infarcted heart and recent studies suggesting that blockade of apoptosis among these cells mitigates postinfarction cardiac remodeling and heart failure. We conclude from our survey that there are many hurdles to surmount before regulation of apoptosis can be clinically applied in the treatment of myocardial infarction and heart failure.

Keywords: apoptosis • myocardial infarction • remodeling • heart failure

Introduction

Although the notion that apoptosis can act as a pathogenic mediator came somewhat later to cardiovascular medicine than to other fields of medicine, research into the role of apoptosis in heart disease has progressed explosively during the past 10 years. Consequently, we now have much information about apoptosis in cardiac cells, collected in vitro and in vivo under a wide variety of pathological conditions using both experimental animal models and specimens from...
heart disease patients, and there are a number of excellent reviews dealing with the role of apoptosis in heart disease [1–11].

Among the various cardiovascular ailments, myocardial infarction (MI) is particularly noteworthy for having high rates of both mortality and morbidity. Patients experiencing MI are at risk of sudden death during the acute stage and then ventricular remodeling and heart failure during the chronic stage, with the most critical determinant of the remodeling being the magnitude of the acute infarct (i.e., the number of dead cardiomyocytes resulting from the acute ischemic insult). In addition, other factors, including late death or hypertrophy of cardiomyocytes, fibrosis and the expression of various cytokines, are associated with the continued disease progression during the chronic stage. Notably, apoptosis has been detected in the heart during all stages of MI, suggesting apoptosis may be responsible for a significant amount of cardiomyocyte death during the acute ischemic stage, as well as for a progressive loss of surviving cells during the subacute and chronic stages. Patients who survive large MIs are at especially high risk of developing such failure. Indeed, patients with post-infarct heart failure account for 44% of candidates for cardiac transplantation [12].

Heart failure is the final outcome of a number of heart diseases. Although the mechanisms for cardiac decompensation have not been fully elucidated, loss of cardiac myocytes has been considered important as well as dysfunction of individual cardiac myocytes for one of the mechanisms. Extensive study now indicates that apoptosis is deeply involved in the pathology of almost all types of heart disease, not only ischemia-related ailments (ischemia-reperfusion, the acute and chronic stages of MI, ischemic cardiomyopathy and hibernating myocardium), but also other heart diseases such as dilated cardiomyopathy. Thus, apoptosis appears to be established as one important mode of cardiomyocyte death that is responsible for the development and worsening of heart failure. Other than ischemic hearts and failing hearts, cardiac arrhythmias is an important disease entity where apoptosis is suggested to play a role in the pathogenesis [13–16].

Nevertheless, no therapeutic intervention has yet been established to address the problem of cardiac apoptosis, nor has there ever been a clinical trial aimed at evaluating a therapeutic approach to the problem. In the present review, we critically assess the relevance of apoptosis to cell death related to MI and heart failure, and the possibility of therapeutic anti-apoptotic interventions.

### Basic concept for apoptosis - apoptosis is a morphological term

Cell death can be classified based on the pathophysiological cause, the molecular mechanism or the morphology of the affected cell (Table 1). Apoptosis is a morphological term coined by Kerr et al. in 1974 [17]. They observed morphological changes in dying cells that were entirely distinct from those of necrosis and speculated that these changes were associated a form of spontaneous cell death. Today, apoptosis is recognized as a fundamental mechanism, a form of programmed cell death that is regulated physiologically and genetically and plays a central role in development, morphogenesis, normal cell turnover, hormone-dependent organ atrophy and immune system function (Table 1) [18, 19]. Moreover, it is now apparent that there are many diseases in which abnormal apoptotic processes are etiologically important or in which apoptosis influences the progression or severity of the disease process. For example, abnormally suppressed apoptosis is related to the growth of neoplasms and autoimmune disorders,

| 1. Based on Cause:                                      |
|--------------------------------------------------------|
| A. accidental cell death                                |
| B. physiological cell death                             |

| 2. Based on Death Machinery:                           |
|--------------------------------------------------------|
| A. passive cell death                                  |
| B. active cell death = programmed cell death           |

| 3. Based on Morphology:                                |
|--------------------------------------------------------|
| A. oncosis (= necrosis)                                |
| B. apoptosis                                           |

---

**Table 1** Classification of mode of cell death - Necrosis versus apoptosis
while abnormally induced apoptosis is seen in acquired immunodeficiency disease (AIDS) and various neurodegenerative disorders [20].

In considering the ultrastructural changes that take place during apoptosis, those in the nucleus might be the most impressive. During apoptosis, nuclear chromatin homogenously condenses, attaches to the nuclear membrane and assumes a crescent, half-moon or horseshoe-like appearance (Fig. 1A). The condensed chromatin is glossy and sharply demarcated. Cell shrinkage accompanied by cytoplasmic condensation also occurs until the cell becomes first multi-lobulated and then fragmented. The nucleus is also fragmented, but other subcellular organelles are preserved in morphological terms until the final stage. The cell fragments, called apoptotic bodies, are enclosed by the plasma membrane, which appears intact so that the cellular contents are not released, and are rapidly phagocytosed by macrophages or neighboring cells. Apoptosis does not lead to inflammation, which is in contrast to necrosis in which an inflammatory response occurs due to rupture of the plasma membrane and release of cellular contents.

Specific DNA fragmentation at nucleosomal units is one of the most characteristic biochemical features of apoptosis [18]. Apoptotic DNA fragmentation is detectable using molecular biological assays, such as DNA gel electrophoresis (Fig. 1B), or in situ labeling of DNA nicks (terminal deoxynucleotidyl transferase (TdT)-mediated dUTP in situ nick end-labeling [TUNEL]) [21] (Fig. 1C) or ligation of DNA strand breaks having one- or two-base 3’ overhangs (Taq polymerase-based in situ ligation) [22].

Necrosis is a general term describing another mode of cell death that differs from apoptosis. The common usage of the term “necrosis” is somewhat problematic, however, because 1) dead cells are so severely degraded by the final stage that it cannot be morphologically determined whether they died via apoptosis or necrosis; and 2) necrosis refers only to an irreversible stage of cell death, even though dying cells generally progress from a reversible to an irreversible stage. To address this issue, Majno and Joris revived an old term, “oncosis,” which refers to cell death accompanied by swelling [23]. They proposed to substitute oncosis for necrosis in cells dying via a process involving cellular swelling or dropsy, and contrasted oncosis with apoptosis, which is accompanied by cellular shrinkage. They then proposed that necrosis be used to refer to the final stage of either apoptosis or oncosis in which advanced degeneration is seen (Fig. 2). We consider this concept excellent, so in this review we will use oncosis instead of the more commonly used necrosis.
The process of apoptosis can be divided into three steps: induction, determination and execution [24]. Induction involves the introduction of apoptotic stimuli to cells. A variety of chemical and mechanical stimuli are capable of inducing apoptosis, including the ligands binding to the Fas receptor or tumor necrosis factor (TNF) receptor, radiation, chemicals, heat and elimination of a growth factor or other hormone. Indeed, activation of pathways leading to determination may vary greatly depending on cell type and specific cell conditions (e.g., the degree of differentiation and where the cell is in the cell cycle). During determination, the second step in the apoptotic process, the signal is transferred to the nucleus, where it affects gene expression. Oncogenes such as c-myc, c-fos, bcl-2 and p53, among others, are expressed, yielding products that either promote or suppress expression or activation of proapoptotic and prosurvival mediators. Finally, during execution the DNA fragmentation and the other morphological changes characteristic of apoptosis occur. In contrast to the diverse pathways leading to induction, execution is well conserved in biochemical terms, and involves specific proteolysis by caspases, a family of aspartyl-specific cysteine proteases, and specific DNA fragmentation by deoxyribonucleases (DNases). There are now more than 10 human caspases known, which can be divided into functional groups [25, 26]. Among apoptosis-related DNases, caspase-activated DNase (CAD) and its inhibitor, inhibitor of CAD (ICAD), were discovered simultaneously [27]. Downstream of the caspases is Acinus (apoptotic chromatin condensation inducer in the nucleus), a factor causing condensation of nuclear chromatin [28]. The factors responsible for cellular shrinkage, budding, and fragmentation are still unknown.

**Apoptosis of cardiomyocytes**

During development, apoptosis contributes to the normal morphogenesis of the heart, as contributes to the morphogenesis of other organs. Apoptotic cardiomyocyte death is known to occur during embryogenesis, while after birth apoptosis is assumed to be involved in the morphogenesis of the conduction system, including the sinus node, AV node and His bundle [29]. In addition, a study in rats found a greater rate of apoptosis of both cardiomyocytes and nonmyocytes in the right ventricle than in the left within days after birth [30]. This is consistent with fact that although there are similar numbers of myocytes in the two ventricles at birth, there is greater number in the mature left ventricle.

Cell death and proliferation are normally in equilibrium in multicellular animals and plants. Consequently, one would expect apoptosis to have only a very limited role in the healthy heart, as the parenchymal cells and terminally differentiated adult cardiomyocytes rarely proliferate, if at all. This prompts one to wonder whether cardiomyocytes might not exhibit the typical apoptosis. Certainly apoptosis accompanied by the typical ultrastructure, caspase-3 activation, and DNA fragmentation can be induced in adult cardiomyocytes by Fas stimulation (Figs. 3 and 4) [31, 32]. Beta-adrenergic pathway
stimulation with isoproterenol induces apoptosis that satisfies the morphological criteria [33], and even a simple cell isolation procedure can induce apoptosis in adult cardiomyocytes [34]. Nevertheless, one in vivo study showed that cardiac cells (both cardiomyocytes and nonmyocytes) have a significantly lower sensitivity to apoptotic stimulation than liver cells (Fig. 5) [32]. Thus, the heart may be distinct in certain ways, though the rate of clearance of apoptotic cardiomyocytes was similar to that of apoptotic hepatocytes (< 24 hours).

**Fig. 3** Scanning (left) and transmission (right) electron micrographs of Fas-induced apoptosis in cultured adult rat cardiomyocytes. Scale bars, 10 μm (left) and 1 μm (right). (A) A normal rod-shaped cell. The nucleus (N), myofibrils and mitochondria appear intact. (B) A round cell showing maximal shrinkage. The cell surface is smooth. The fragmented nuclei (N) containing condensed chromatin with a doughnut-like shape, condensed mitochondria, and a lipid-like structure are seen. Myofibril rows are completely disrupted. Inset: higher magnification of the area surrounded by the square showing details of the mitochondrial changes. Arrow heads point to wrinkled bodies within the condensed mitochondria. (C) A cardiomyocyte forming apoptotic bodies (cellular fragmentation). The surface of each body is smooth, and each contains various subcellular organelles, including condensed mitochondria with wrinkled bodies and disrupted myofibrils. (Reprinted from Maruyama et al. Am J Pathol. 2001; 159: 683–91 with permission from the American Society for Investigative Pathology)

**Apoptosis in myocardial infarction**

Apoptosis among in vivo cardiomyocytes was first reported by Gottlieb et al. [35]. In that case, apoptosis was induced by ischemia/reperfusion in rabbit hearts. The apoptosis was identified based on the presence of fragmented DNA in electrophoretic gels, on in situ nick end-labeling assays and on electron microscopic analysis showing the presence of clumped chromatin scattered within the nucleus. In the same year, an in
vitro experiment showed that hypoxia induced DNA fragmentation accompanied by overexpression of Fas mRNA in cultured neonatal cardiomyocytes [36], and somewhat later persistent ischemia without reperfusion was shown to induce a substantial number of apoptotic cardiomyocytes in areas of acute infarction in rat hearts [37]. In humans, DNA fragmentation was detected in cardiomyocytes from hearts autopsied following fatal MI [38]. Since publication of these studies, numerous other studies on the relation between apoptosis and myocardial ischemia and infarction have been published, for the most part confirming the aforementioned observations [5]. Regardless of the cause of cardiomyocyte death (i.e., ischemia, reperfusion or both) studies conducted with several animal models and on tissues from humans suggest that both apoptosis and oncosis are responsible for acute ischemia-induced cardiomyocyte death [39–44].

It is important to note, however, that all of the evidence for apoptosis in cardiomyocytes cited above is indirect, based on detection of DNA fragmentation and/or so-called apoptosis-related factors, and that there is little evidence of apoptotic ultrastructure, which is the gold standard for diagnosing apoptosis. Indeed, the electron microphotograph appearing in the pioneering study by Gottlieb et al. [35] shows not an apoptotic cell but a typical onotic cardiomyocyte frequently found when a heart is reperfused after ischemia; it is a well-known example of contraction band necrosis [45, 46]. Thus, the simple use of TUNEL-positivity and DNA ladder detection for determination of apoptosis can result in misunderstandings as to the mode of cell death, as has repeatedly been cautioned [47–53]. There are several reasons for this. First, TUNEL detects both single-strand and double-strand DNA breaks with free 3’-OH terminals, and may therefore detect not only apoptosis-induced DNA breaks but also ones induced by oncosis. Second, DNA ladders may not be specific for cardiomyocyte apoptosis in vivo since nonmyocytes cells, whose numbers greatly exceed those of myocytes in myocardial tissue, may contaminate tissue samples. In addition, DNA ladders are also detected in typical oncosis models created by direct plasma membrane damage [50]. Third, DNA fragmentation is not necessarily related to apoptotic morphology in the

**Fig. 4** Transmission electron photomicrographs of rat myocardium injected with soluble Fas ligand. Scale bars, 1 μm. (A) The nucleus shows glossy and well-demarcated condensed chromatin with a doughnut-like shape. (B) Nuclear fragmentation (arrows) is apparent. (C) Budding (surrounded by arrowheads) in a cardiomyocyte. (Reproduced from Hayakawa et al. *Circulation* 2002; 105: 3039–45)
nucleus [54, 55]. Notably, the same warning was recently raised in the field of neurology, as it was found that neuronal cell death due to ischemic or degenerative disorders is unrelated to apoptosis, despite the fact that the neurons showed positive TUNEL reactions [56, 57].

We emphasize the importance of using electron microscopy to assess apoptotic morphology, particularly preservation of membrane integrity. When we employed electron microscopy combined with TUNEL (EM-TUNEL), we found TUNEL-positivity in cardiomyocytes that had already exhibited irreversible oncosis with ruptured plasma membranes several hours earlier (Fig. 6) [58]. We found no cardiomyocytes exhibiting apoptotic ultrastructure in infarced areas. Thus, the so called “apoptotic cardiomyocytes” in the infarced areas were actually irreversibly oncosic cells with fragmented DNA. This implies that although some final steps in the apoptotic process may be activated in infarcted tissue, this activation likely has no relevance to the extent of infarction already determined by irreversibly oncosic cardiomyocytes. Furthermore, although loss of mitochondrial permeability transition has been observed in the heart rendered ischemia/reperfusion and linked to cardiomyocyte apoptosis [59, 60], a recent study denied that linkage [61], supporting the doubt of cardiomyocyte apoptosis during ischemia/reperfusion.

**Apoptosis in heart failure**

Large MIs lead to severe chronic heart failure with unfavorable remodeling of the left ventricle that is characterized by ventricular dilation and diminished cardiac performance [62]. The ultimate size of acute infarct, which can be determined within several hours after the onset [63], is the most critical determinant of subsequent heart failure. However, many other factors, including late cardiomyocyte death or hypertrophy, fibrosis
and expression of various cytokines are also associated with disease progression [64–67]. When subjected to a chronic load, the heart maintains an appropriate functional level through cardiomyocyte hyperfunctionality and hypertrophy. Within the loaded cardiomyocytes, a cascade of protein kinases is activated, which in turn leads to augmented gene transcription and protein synthesis and then to induction of cardiomyocyte hypertrophy. If the load is excessive or long lasting, however, cardiac hypertrophy decompensates into cardiac dilation and failure. The mechanisms responsible for cardiac decompensation are not well understood but likely involve progressive contractile dysfunction and/or progressive cardiomyocyte degeneration and death. Loss of cardiomyocytes during either the acute or chronic stage of MI directly contributes to contractile dysfunction. In addition, apoptosis is now suggested to be involved in the acute ischemic death of cardiomyocytes, as well as in the dropout of surviving cardiomyocytes during the chronic stage of MI.

Narula et al. and Olivetti et al. found apoptotic cardiomyocytes (TUNEL-positive cardiomyocytes) in the explanted hearts obtained during cardiac transplantation from patients with heart failure resulting from ischemic or dilated cardiomyopathy; they suggested that the loss of cardiomyocytes via apoptosis may contribute to the
progression of heart failure [68, 69]. Subsequent studies showed 1) that the incidence of apoptotic cardiomyocytes exhibiting fragmented DNA in TUNEL assays is increased significantly at the borders of subacute and old infarcts, though there is wide variation in the frequency (0.05%–35%) [70, 71]; 2) that persistent and progressive loss of cardiomyocytes in areas neighboring infarcts due to apoptosis occur during the subacute stage (up to 60 days after the onset) of MI [72]; and 3) that the incidence of cardiomyocyte apoptosis was significantly reduced when the responsible coronary artery was recanalized [73]. In that regard, the term “hibernation” refers to a chronic condition of severe energy deprivation in the myocardium due to chronic or repetitive underperfusion associated with reversible contractile dysfunction [74, 75]. Elsässer et al. [76] showed the presence of apoptosis in human hibernating myocardium and postulated its possible role in tissue deterioration, though Dispersyn et al. [77] were unable to confirm this finding; they observed cardiomyocyte dedifferentiation, but not extensive degeneration through apoptosis, in human chronic hibernating myocardium under the electron microscope.

Left coronary artery ligation in experimental animals leads to MI and subsequent development of progressive heart failure. In these animals, cardiomyocytes with fragmented DNA were found among the apparently surviving myocytes at the border of old infarcted tissue in rats and mice [66, 78–82]. Moreover, some studies reported a relation between the rate of apoptosis among cardiomyocytes (incidence of TUNEL-positive cardiomyocytes) and left ventricular remodeling (dilation). Likewise, using dogs, Sharov et al. showed that 3 to 4 months after surgery, there were significantly larger numbers of apoptotic cardiomyocytes in hearts with MIs induced by transcatheter coronary embolization, mainly distributed at the borders of the infarction scars, than in sham-operated hearts [83]. Such coronary embolization was also associated with development of heart failure, caspase-3 activation, and increased numbers TUNEL-positive cardiomyocytes in sheep [84, 85]. Moreover, Chen et al. reported apoptosis in subendocardial regions of hibernating areas of the pig heart and emphasized the importance of ongoing apoptotic cell death in this situation [86].

In ultrastructural terms, however, there is no evidence of apoptosis in cardiac myocytes in hearts failing as a result of ischemic heart disease or any other origin. The detection of apoptosis in heart failure has generally entailed the use of indirect methods such as DNA fragmentation and apoptosis-related factors such as caspases. Activation of caspases is strongly indicative of apoptosis because there is no conclusive evidence that caspase-independent apoptosis exists [87]. Especially, evidence of activated caspase-3, one of the effector caspases, is considered useful for detection of apoptosis. Activated caspase-3 was detected by several reports in cardiomyocytes of failing hearts due to dilated cardiomyopathy [88] or ischemic heart disease [72, 73]. However, such positive data were challenged [89, 90] and the specificity remains undetermined because of too high rate of the positive cells [91]: more than 25% of the myocytes were active caspase-3-positive at the site of infarction [72, 73]. Thus, it is still unclear whether the detected active caspases in the previous reports really indicated apoptosis. In fact, the incidences of apoptotic cardiomyocytes detected by TUNEL or activated caspase-3 in diseased hearts are too high for these cells to be considered dead; considering that cardiomyocyte replication in adults is rare and that apoptosis progresses rapidly, such a continuous and massive loss of cardiomyocytes without corresponding replication would rapidly lead to clinical crisis. Nevertheless, no such clinical crisis is observed in most patients. Using electron microscopic TUNEL, we showed that in biopsy specimens from the hearts of patients with dilated cardiomyopathy, TUNEL-positive cells were neither apoptotic nor oncotic, but were living cells (Fig. 7) [92]. We suggested that such cardiomyocytes were undergoing DNA repair because they always expressed proliferating cell nuclear antigen (PCNA), an indicator of DNA replication and repair [93], but never Ki-67, a replication-associated antigen [94]. Furthermore, a subsequent study reported expression of the splicing factor SC-35 in the TUNEL-positive cardiomyocytes in hearts of patients with dilated cardiomyopathy, indicating them to be alive [95], which we confirmed not only in failing hearts such as dilated cardiomyopathy and postmyocarditis but also in other heart diseases (i.e., hypertrophic cardiomyopathy and hypertensive heart disease) [90].
If the TUNEL-positive cardiomyocytes had really been undergoing apoptosis, its incidence must have affected the prognosis of the patients. However, no relationship was found between the apoptotic index in endomyocardial biopsies based on in situ DNA nick end-labeling by TUNEL and the patients’ prognosis (survival, hospitalization, and worsening of cardiac function) [96].

**Apoptotic signaling in the cardiomyocyte**

Knowledge about apoptotic signaling has been largely obtained from studies using proliferating or undifferentiated cells; apoptotic signaling in cardiomyocytes is far less well understood. It is generally assumed, however, that apoptotic signaling is essentially similar among cells. Fig. 8 schematically summarizes the apoptotic signal transduction pathways in cardiomyocytes.

In the heart rendered acute ischemia, a substantial number of genes and their products (more than 100) are alternately regulated or activated/inactivated; among these are the so-called apoptosis-related factors. In humans, for example, Bcl-2 is overexpressed in the surviving cardiomyocytes around acute infarcts, which is substituted by Bax during the chronic stage of the infarction [97]. Fas is also reportedly overexpressed in cardiomyocytes neighboring acute infarcts in a rat infarction model [40, 98]. Plasma concentrations of soluble Fas are increased in parallel to the severity of heart failure in humans [99], as is soluble Fas ligand [100], but there may not be a direct temporal or spatial relationship between Fas expression and cardiomyocyte apoptosis in infarcted hearts [101].

The present review does not intend to describe molecular biological aspects of cardiomyocyte apoptosis in detail. For further understanding that field, please refer to other excellent reviews [1, 4–7, 11, 102].

**Prevention of apoptosis**

**Cardiomyocyte as the target**

An understanding of apoptotic signaling in cardiomyocytes may help in developing therapeutic
Ischemia, cardiac hypertrophy resulting from increased afterload, and cardiac remodeling are possible triggers for cardiomyocyte apoptosis. β-Blockers, angiotensin converting enzyme (ACE) inhibitors, antioxidants and angiogenic therapy are effective suppressors of those triggers. Blockade of signaling via death receptors such as the Fas receptor and tumor necrosis factor-receptor type 1 (TNFR1) is possible through competitive inhibition by soluble Fas and soluble TNFR1 or through expression of death receptor decoys. During determination, it may be possible to inhibit apoptosis by stimulating inhibitory factors [e.g., Bcl-2, Bcl-xL, apoptosis repressor with a caspase recruitment domain (ARC) [134] and FLAME-1 [135], by suppressing proapoptosis factors [e.g., Bax, Bad, BID, FADD [136], MKK3/p38, Gα and Gq] by treatment with growth factors [e.g., insulin-like growth factor-1 (IGF-1), cardiotrophin-1, and neuregins], or by activation of various mediators and kinases [e.g., gp130 subunit, extracellular signal-regulated kinase (ERK), and phosphoinositol-3-kinase/Akt]. During execution, inhibition of apoptosis may be possible by inhibiting caspase activation using caspase inhibitors or inhibitors of apoptosis proteins [e.g., IAP-1, IAP-2 and X-chromosome-linked IAP (XIAP) [137]. Apaf-1, apoptosis-activating factor; c-FLIP, cellular FLICE (FADD-like IL-1-convertin enzyme)-inhibitory protein; MKP-1, mitogen-activated protein kinase phosphatase-1; CAD, caspase-activated DNase; ICAD, inhibitor of CAD.

Fig. 8 Apoptotic signal transduction in cardiomyocytes and anti-apoptotic strategies. Ischemia, cardiac hypertrophy resulting from increased afterload, and cardiac remodeling are possible triggers for cardiomyocyte apoptosis. β-Blockers, angiotensin converting enzyme (ACE) inhibitors, antioxidants and angiogenic therapy are effective suppressors of those triggers. Blockade of signaling via death receptors such as the Fas receptor and tumor necrosis factor-receptor type 1 (TNFR1) is possible through competitive inhibition by soluble Fas and soluble TNFR1 or through expression of death receptor decoys. During determination, it may be possible to inhibit apoptosis by stimulating inhibitory factors [e.g., Bcl-2, Bcl-xL, apoptosis repressor with a caspase recruitment domain (ARC) [134] and FLAME-1 [135], by suppressing proapoptosis factors [e.g., Bax, Bad, BID, FADD [136], MKK3/p38, Gα and Gq] by treatment with growth factors [e.g., insulin-like growth factor-1 (IGF-1), cardiotrophin-1, and neuregins], or by activation of various mediators and kinases [e.g., gp130 subunit, extracellular signal-regulated kinase (ERK), and phosphoinositol-3-kinase/Akt]. During execution, inhibition of apoptosis may be possible by inhibiting caspase activation using caspase inhibitors or inhibitors of apoptosis proteins [e.g., IAP-1, IAP-2 and X-chromosome-linked IAP (XIAP) [137]. Apaf-1, apoptosis-activating factor; c-FLIP, cellular FLICE (FADD-like IL-1-converting enzyme)-inhibitory protein; MKP-1, mitogen-activated protein kinase phosphatase-1; CAD, caspase-activated DNase; ICAD, inhibitor of CAD.
strategies to prevent cardiomyocyte cell death. In Fig. 5, possible therapeutic interventions are indicated by underlines. Of those, the most important and best studied approach may be caspase inhibition. For example, when Yaoita et al. applied a caspase inhibitor, YVAD.fmk, to a rat acute MI model, they observed not only a reduction in the numbers of TUNEL-positive cardiomyocytes but also a reduction in acute infarct size [103]. This finding was subsequently confirmed using other types of caspase inhibitor [104–107], though two studies using a rabbit model (including ours) could not confirm that caspase inhibitors reduced infarct size [108, 109]. There is also a study showing caspase inhibition to have a beneficial effect on postinfarction functional recovery, though this effect appears to be independent of the anti-apoptotic effect, suggesting caspase inhibitors have actions other than inhibition of apoptosis [110]. Conversely, still another study reported an infarct-reducing effect of a caspase inhibitor without functional recovery [111]. Clearly, the therapeutic effect of caspase inhibitors on acute MI remains controversial.

In the actual clinical settings, a number of large-scale trials have shown effectiveness of angiotensin converting enzyme (ACE) inhibitors and β-blockers for preventing development and progress of heart failure after infarction [112–115], although it is unclear whether the beneficial effects mechanically depend on the anti-apoptosis. In contrast, a clinical benefit of TNF-α antibodies on the prognosis of moderate-to-severe chronic heart failure was ruled out by results of recent clinical trials [116, 117].

**Nonmyocytes as the target**

What was infarcted myocardial tissue containing dead cardiomyocytes and infiltrating inflammatory cells during the acute stage is instead comprised of scar tissue containing few cellular components by the chronic stage. This transformation is mediated during the subacute stage by granulation tissue comprised of numerous myofibroblasts and a rich vasculature [118, 119]. During the subacute phase of MI, the nonmyocyte population increases due to both proliferation and infiltration, affecting postinfarct-
tion remodeling through the synthesis of extracellular matrix and/or the secretion of cytokines and local hormones that interact with cardiomyocytes and nonmyocytes alike [120]. As evidenced by ultrastructure and DNA fragmentation, apoptosis is the mechanism by which nonmyocytes present in infarcted tissues, including leukocytes, myofibroblasts, macrophages and endothelial cells, are eliminated from the subacute infarction (Figs. 9 and 10) [121, 122].

This raises the question, what would happen if this apoptosis, which occurs during the natural course of healing, was artificially inhibited? We recently reported that blockade of apoptosis in granulation tissue using the pancaspase inhibitor Boc-Asp-fmk significantly improves survival rate and mitigates both ventricular remodeling and dysfunction during the chronic stage in infarct-bearing rats (Fig. 11) [123]. Possible mechanisms to explain such beneficial effects might be preservation of infarcted wall thickness, which could reduce wall stress, and preservation of myofibroblasts, which could promote infarct contraction. It was also found

Fig. 9 Electron micrographs showing apoptosis of myocardial interstitial cells within infarcted areas: inflammatory cells 2 days after onset of MI (Panel A) and granulation tissue 2 weeks after onset of MI (B through D). Scale bars, 1 μm. (A) Nuclear chromatin is eccentric in the leukocyte. The plasma membrane is not ruptured. (B) A typical apoptotic myofibroblast. The arrow points to the homogeneously condensed nucleus with a glossy appearance; arrowheads point to intracytoplasmic microfilaments. (C) An apoptotic macrophage. The nucleus with peripherally condensed chromatin is seen in the center (N), and many phagolysosomes are seen in the cytoplasm. (D) Condensed nucleus (N) of an apoptotic capillary endothelial cell. A red blood cell (RBC) is seen within the capillary lumen. (Rprinted from Takemura et al. Circ Res. 1998; 82: 1130–8)
that in mice, granulation tissue cell apoptosis is at least in part Fas/Fas ligand-dependent [124]. More recently, we found that transforming growth factor-β (TGF-β) could accelerate the granulation tissue cell apoptosis in infarcted area, and that the inhibition of TGF-β signal during the subacute stage of MI mitigated the post-MI ventricular remodeling and heart failure [125]. Taken together, these findings imply the utility of a new therapeutic strategy against postinfarction heart failure - i.e., postinfarction blockade of granulation tissue cell apoptosis – which would be applicable in patients who missed the chance for coronary reperfusion therapy at the acute stage of their MI [126].

**Autophagy in heart disease**

Autophagic cell death is another form of programmed cell death that has recently attracted attention [127]. Although autophagy was originally thought to be a physiological process for eliminating unnecessary subcellular organelles, as apoptosis is for eliminating unnecessary cells, cells do die *via* autophagic mechanisms, and terminally differentiated cells, like neurons and cardiomyocytes, are thought to be more sensitive to autophagy than other cell types [128, 129]. In contrast to apoptosis, autophagic cell death is caspase-independent. Vacuolar degeneration is its most characteristic feature, with cells exhibiting large vacuoles (autophagosomes) containing degraded mitochondria and myelin-like structures. Cathepsin family proteins, the proteases within lysosomes, play important roles here. Recently, cardiomyocyte death showing characteristics of autophagy was reported in human heart failure due to dilated cardiomyopathy, valvular heart disease, hypertensive heart disease, and chronic ischemia [95, 130–133]. Notably, the incidence of such autophagic cardiomyocytes in failing hearts was reportedly greater than the incidence of apoptotic cells. We have also shown abundant and severe autophagic degeneration in cardiomyocytes of the UM-X7.1 strain hamster, an animal model of human dilated cardiomyopathy (Fig. 12) [134]. In this study, we suggested a linkage between autophagic degeneration and cell death. Strictly speaking, however, it is still undetermined whether abnormal autophagy is the primary cause of cardiomyocyte death, the result of a failed compensatory mechanism, or a phenomenon unrelated with pathogenesis in heart failure. Additional investigation will be necessary to determine the precise role of autophagic cardiomyocyte death in heart disease.
Concluding remarks

Although more than 10 years have passed since the first description of apoptosis in MI, this topic continues to attract much attention. Perhaps because apoptosis is considered to be more controllable than necrosis, not only its scientific significance but also the expectation of a therapeutic application drives research on the topic. In that context, the present review may seem somewhat cautionary, but the fact remains that there are many hurdles to surmount before regulation of apoptosis can be clinically applied in the treatment of MI and any other heart disease. The most critical issue may be definitive detection of cardiomyocyte apoptosis in pathological hearts, which has not yet been achieved during any stage of MI. Electron microscopy is the most definitive approach, but it is technically difficult and time-consuming, and it is not a good technique for quantification. Development of a more convenient but highly selective assay would be desirable. In addition, it is still unclear to what extent apoptosis contributes to the pathogenesis or aggravation of heart disease - i.e., it remains unknown whether a reduction of apoptosis would actually improve outcomes in heart disease? Finally, manipulation of apoptosis almost certainly entails some risk of adverse effects. All of these issues will have to be resolved in the future.

Aknowledgements

This work was supported in part by Research Grants from the Ministry of Education, Science, and Culture of Japan (No.16590669), from Mitsubishi Pharma Research Foundation, and from Takeda Science Foundation. We thank Rumi Maruyama, Akiko Tsujimoto, Hatsue Ohshika, and Kazuko Goto for excellent technical assistance.
References

1. MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997; 81: 137–44.

2. Davies MJ. Apoptosis in cardiovascular disease. Heart 1997; 77: 498–501.

3. Kang PM, Izumo S. Apoptosis and heart failure: A critical review of the literature. Circ Res. 2000; 86: 1107–13.

4. Elsasser A, Suzuki K, Schaper J. Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure. J Mol Cell Cardiol. 2000; 32: 711–24.

5. Yatio H, Ogawa K, Maehara K, Maruyama Y. Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction. Cardiovasc Res. 2000; 45: 630–41.

6. Narula J, Kolodgie FD, Virmani R. Apoptosis and heart failure. From postnatal morphogenesis to adult cardiomyopathy. Circulation 1997; 86: 137–44.

7. Gill C, Mestril R, Samali A. Losing heart: the role of apoptosis in heart disease - a novel therapeutic target? FASEB J. 2002; 16: 135–46.

8. Abbate A, Bondi-Zoccai GG, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol. 2002; 193: 145–53.

9. Rodriguez M, Lucchesi BR, Schaper J. Apoptosis in myocardial infarction. Ann Med. 2002; 34: 470–9.

10. Takemura G, Fujiwara H. Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther. 2004; 104: 1–16.

11. Reeve JL, Duffy AM, O’Brien T, Samali A. Don’t lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. J Cell Mol Med. 2005; 9: 609–22.

12. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant. 2000; 19: 909–31.

13. James TN, St Martin E, Willis PW 3rd, Lohr TO. Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and intermodal pathways. Circulation 1996; 93: 1424–38.

14. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med. 1996; 335: 1190–6.

15. Nishikawa T, Ishiyama S, Nagata M, Sakomura Y, Nakazawa M, Momma K, Hiroe M, Kasajima T. Programmed cell death in the myocardium of arrhythmogenic right ventricular cardiomyopathy in children and adults. Cardiovasc Pathol. 1999; 8: 185–9.

16. Nagata M, Hiroe M, Ishiyama S, Nishikawa T, Sakomura Y, Kasanuki H, Toyosaki T, Marumo F. Apoptotic cell death in arrhythmogenic right ventricular cardiomyopathy: a comparative study with idiopathic sustained ventricular tachycardia. Jpn Heart J. 2000; 41: 733–41.

17. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–57.

18. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555–6.

19. Cohen JJ. Programmed cell death in the immune system. Adv Immunol. 1991; 50: 55–85.

20. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251–4.

21. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992; 119: 493–501.

22. Didenko VV, Hornsby PJ. Presence of double-strand breaks with single-base 3’ overhangs in cells undergoing apoptosis but not necrosis. J Cell Biol. 1996; 135: 1369–76.

23. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995; 146: 3–15.

24. Tanuma S. Molecular mechanisms of apoptosis. In: Sluyser M, editor. Apoptosis in normal development and cancer. London, Taylor & Francis; 1996. p. 39–59.

25. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312–6.

26. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000; 157: 1415–30.

27. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43–50.

28. Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoned A, Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 1999; 401: 168–73.

29. James TN. Normal and abnormal consequences of apoptosis in the human heart. From postnatal morphogenesis to paroxysmal arrhythmias. Circulation 1994; 90: 556–73.

30. Kajstura J, Mansukhani M, Cheng W, Reiss K, Krajewski S, Reed JC, Quaini F, Sonnenblick EH, Anversa P. Programmed cell death and expression of the protooncogene bcl-2 in myocytes during postnatal maturation of the heart. Exp Cell Res. 1995; 219: 110–21.

31. Maruyama R, Takemura G, Aoyama T, Hayakawa K, Koda M, Kawase Y, Qiu X, Ohno Y, Minatoguchi S, Miyata K, Fujiwara T, Fujiwara H. Dynamic process of apoptosis in adult rat cardiomyocytes analyzed using 48-hour videomicroscopy and electron microscopy: beating and rate are associated with the apoptotic process. Am J Pathol. 2001; 159: 683–91.

32. Hayakawa K, Takemura G, Koda M, Kawase Y, Maruyama R, Li Y, Minatoguchi S, Fujiwara T, Fujiwara H. Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in vivo in adult cardiac cells. Circulation 2002; 105: 3039–45.

33. Maruyama R, Takemura G, Tohse N, Ohkusa T, Ikeda Y, Tsuchiya K, Minatoguchi S, Matsuaki M, Fujiwara T, Fujiwara H. Synchronous progression of calcium transient-dependent beating and sarcomere destruction in...
apoptotic adult cardiomyocytes. Am J Physiol Heart Circ Physiol. 2006 (in press)

34. Kato S, Takemura G, Maruyama R, Aoyama T, Hayakawa K, Koda M, Kawase Y, Li Y, Minatoguchi S, Fujiwara T, Fujiwara H. Apoptosis, rather than oncosis, is the predominant mode of spontaneous death of isolated adult rat cardiac myocytes in culture. Jpn Circ J. 2001; 65: 743–8.

35. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994; 94: 1621–8.

36. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 1994; 75: 426–33.

37. Fliss H, Gattiniger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 1996; 79: 949–56.

38. Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura M, Jie T, Ito K. DNA fragmentation of a human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol. 1995; 146: 1325–31.

39. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor 1 in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA. 1995; 92: 8031–5.

40. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Fridman J, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 1996; 74: 86–107.

41. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997; 95: 320–23.

42. James TN. The variable morphological coexistence of apoptosis and necrosis in human myocardial infarction: significance for understanding its pathogenesis, clinical course, diagnosis and prognosis. Coron Artery Dis. 1998; 9: 291–307.

43. Zhao QZ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, Guyton RA, Vinten-Johansen J. Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res. 2000; 45: 651–60.

44. Freude B, Masters TN, Robiezek F, Fokin A, Kostin S, Zimmermann R, Ullmann C, Lorenz-Meyer S, Schaper J. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol. 2000; 32: 197–208.

45. Jennings RB, Baum JH, Herdson PB. Fine structural changes in myocardial ischemic injury. Arch Pathol. 1965; 79: 135–43.

46. Kloner RA, Ganote CE, Whalen DA Jr, Jennings RB. Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol. 1974; 74: 399–422.

47. Collins RJ, Harmon BV, Gobe GC, Kerr JFR. Intermolecular DNA cleavage should not be the sole criterion for identifying apoptosis. Int J Radiat Biol. 1992; 61: 451–3.

48. Charriaut-Marlangue C, Ben-Ari Y. A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 1995; 7: 61–4.

49. Kockx MM, Muhring J, Bortier H, De Meyer GR, Jacob W. Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Am J Pathol. 1996; 148:1771–7.

50. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. Intermolecular DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol. 1997; 151: 1205–13.

51. Kockx MM, Muhring J, Knaapen MW, de Meyer GR. RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. Am J Pathol. 1998; 152: 885–8.

52. Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 1998; 98: 1355–7.

53. Kang PM, Iizumo S. Apoptosis in heart failure: is there light at the end of the tunnel (TUNEL)? J Card Fail. 2000; 6: 43–6.

54. Sakahira H, Enari M, Ohsawa Y, Uchiyama Y, Nagata S. Apoptotic nuclear morphological change without DNA fragmentation. Curr Biol. 1999; 9: 543–6.

55. Takemura G, Kato S, Aoyama T, Hayakawa Y, Kanoh M, Maruyama R, Arai M, Nishigaki K, Minatoguchi S, Fukuda K, Fujiwara T, Fujiwara H. Characterization of ultrastructure and its relation with DNA fragmentation in Fas-induced apoptosis of cultured cardiac myocytes. J Pathol. 2001; 193: 546–56.

56. Kanazawa I. How do neurons die in neurodegenerative diseases? Trends Mol Med. 2001; 7: 339–44.

57. Graeber MB, Moran LB. Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol. 2002; 12: 385–90.

58. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, Fujiwara T, Fujiwara H. “Apoptotic” myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with In situ nick end-labeling. Circulation 1998; 98: 1422–30.

59. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res. 2003; 93: 292–301.

60. Borutaite V, Jekabsone A, Morkuniene R, Brown GC. Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia. J Mol Cell Cardiol. 2003; 35: 357–66.

61. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophillin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652–8.

62. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Am J Cardiol. 1995; 46: 455–66.

63. Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol. 1993; 72: 13G–21G.
64. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, Alderman JD, Ferguson JJ, Safian RD, Grossman W. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. *Circulation* 1986; 74: 693–702.

65. Weisman HF, Bush DE, Mannisi JA, Weisfeldt ML, Healy B. Cellular mechanisms of myocardial infarct expansion. *Circulation* 1988; 78: 186–201.

66. Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, Clark WA, Krajewski S, Reed JC, Olivetti G, Anversa P. Programmed myocyte cell death affects the viable myocardium after infarction in rats. *Exp Cell Res.* 1996; 226: 316–27.

67. Shan K, Kurrelmeyer K, Seta Y, Wang F, Ribas Z, Deswal A, Lee-Jackson D, Mann DL. The role of cytokines in disease progression in heart failure. *Curr Opin Cardiol.* 1997; 12: 218–23.

68. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. *N Engl J Med.* 1996; 335: 1182–9.

69. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. *N Engl J Med.* 1997; 336: 1131–41.

70. Saraste A, Pulkki K, Kallajoki M, Heikkila P, Laine P, Mattila S, Nieminen MS, Parvinen M, Voipio-Pulkki LM. Cardiomyocyte apoptosis and progression of heart failure to transplantation. *Eur J Clin Invest.* 1999; 29: 380–6.

71. Latif N, Khan MA, Birks E, O’Farrell A, Westbrook J, Dunn MJ, Yacoub MH. Uregulation of the Bcl-2 family of proteins in end stage heart failure. *J Am Coll Cardiol.* 2000; 35: 1769–77.

72. Baldi A, Abbate A, Bussani R, Patti G, Melfi R, Angelini A, Dobrina A, Rossiello R, Silvestri F, Baldi F, Di Sciascio G. Apoptosis and post-infarction left ventricular remodeling. *J Mol Cell Cardiol.* 2002; 34: 165–74.

73. Abbate A, Bussani R, Biondi-Zoccai GG, Rossiello R, Silvestri F, Baldi F, Biasucci LM, Baldi A. Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at postmortem examination in humans late after an acute myocardial infarction. *Circulation* 2002; 106: 1051–4.

74. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemich ventricular dysfunction. *Circulation* 1982; 66: 1146–9.

75. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the “hibernating myocardium”. *J Am Coll Cardiol.* 1986; 8: 1467–70.

76. Elsasser A, Schlepper M, Klocvorkon WP, Cai WJ, Zimmermann R, Muller KD, Strasser R, Kostin S, Gagel C, Munkel B, Schaper W, Schaper J. Hibernating myocardium: an incomplete adaptation to ischemia. *Circulation* 1997; 96: 2920–31.

77. Dispersyn GD, Ausma J, Thöne F, Flameng W, Vanoverschelde JL, Allessie MA, Ramaekers FC, Borgers M. Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis. *Cardiovasc Res.* 1999; 43: 947–57.
91. Koda M, Takemura G, Kanoh M, Hayakawa K, Kawase Y, Maruyama R, Li Y, Minatoguchi S, Fujiwara T, Fujiwara H. Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure. J Pathol. 2003; 199: 229–36.

92. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, Noda T, Fujiwara T, Fukuda K, Minatoguchi S, Fujiwara H. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation 1999; 99: 2757–64.

93. Shiyyi MKK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992; 69: 367–74.

94. Sawhney N, Hall PA. Ki67: structure, function, and new antibodies. J Pathol. 1992; 168: 161–2.

95. Knaapen MW, Davies MJ, De Bie M, Haven AJ, Martinet W, Kockx MM. Apoptotic versus autophagic cell death in heart failure. Cardiovasc Res. 2001; 51: 304–12.

96. Okada H, Takemura G, Kanoh M, Hayakawa K, Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Nakamura N, Aoyama T, Shirakabe M, Shirakawa K, Fujiwara H. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. J Am Coll Cardiol. 1998; 31: 132–42.

97. Shivji MKK, Kenny MK, Wood RD. Expression of bcl-2 protein, an inhibitor of apoptosis, in ventricular myocytes from patients with dilated cardiomyopathy. Circulation 1992; 69: 367–74.

98. Okamura T, Miura T, Takemura G, Fujiwara H, Nishigaki K, Minatoguchi S, Kimura M, Ikeda Y, Iwata M, Matsuoka M. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rabbit heart. Cardiovasc Res. 2000; 45: 642–50.

99. Nishigaki K, Minatoguchi S, Seishima M, Asano K, Jeremias I, Kupatt C, Martin-Villalba A, Habazettl H, Fujiwara H. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. Am J Cardiol. 1997; 29: 1214–20.

100. Yamaguchi S, Yamaoka M, Okuyama M, Nitoube J, Fukui A, Shirakabe M, Shirakawa K, Nakamura N, Tomoike H. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol. 1999; 83: 1500–3.

101. Feng QZ, Li TD, Wei LX, Qiao X, Yi J, Wang L, Yang TS. Temporospatial dissociation between the expression of Fas and apoptosis after coronary occlusion. Mol Pathol. 2003; 56: 362–7.

102. Gupta S, Knowlton AA. HSP60, Bax, apoptosis and the heart. J Cell Mol Med. 2005; 9: 51–8.

103. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998; 97: 276–81.

104. Holly TA, Drinie A, Byun Y, Nakamura S, Harris K, Klocke FJ, Cryns VL. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol. 1999; 31: 1709–15.

105. Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000; 130: 197–200.

106. Kovaes P, Bak I, Szendrei L, Vecsernes M, Varga E, Blasig IE, Tosaki A. Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/reperfused rat hearts. Naunyn Schmiedebergs Arch Pharmacol. 2001; 364: 501–7.

107. Zhao QZ, Morris CD, Budde JM, Wang NP, Muraki S, Sun HY, Guyton RA. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res. 2003; 59: 132–42.

108. Okamura T, Miura T, Takemura G, Fujiwara H, Iwamoto H, Kawamura S, Kimura M, Ikeda Y, Iwata M, Matsuoka M. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rabbit heart. Cardiovasc Res. 2000; 45: 642–50.

109. Minatoguchi S, Kariya T, Uno Y, Arai M, Nishida Y, Hashimoto K, Wang N, Aoyama T, Takemura G, Fujiwara T, Fujiwara H. Caspase-dependent and serine protease-dependent DNA fragmentation of myocytes in the ischemia-reperfused rabbit heart: these inhibitors do not reduce infarct size. Jpn Circ J. 2001; 65: 907–11.

110. Ruutten H, Badorff C, Ihling C, Zeiher AM, Dammel S. Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects. J Am Coll Cardiol. 2001; 38: 2063–70.

111. Perrin C, Ecarnot-Laubriet A, Vergely C, Rochette L, Calpain and caspase-3 inhibitors reduce infarct size and post-ischemic apoptosis in rat heart without modifying contractile recovery. Cell Mol Biol. (Noisy-le-grand) 2003; 49: OL497–505.

112. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316: 1429–35.

113. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991; 325: 293–302.

114. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349–55.

115. CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13.

116. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of
Mallory G, White P, Salcedo-Salga J. Mann DL, McMurray JJ, Packer M, Swedberg K, Hayakawa K, Takemura G, Kanoh M, Li Y, Koda M, Takemura G, Ohno M, Hayakawa Y, Misao J, Kanoh KS, Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Fishbein MC, Maroko PR. Li Y, Takemura G, Kosai K, Takahashi T, Okada H, Minatoguchi S, Fujiwara T, Fujiwara H, Weber KT. Koseki T, Inohara N, Chen S, Nunez G. Miyata S, Takemura G, Kawase Y, Li Y, Okada H, Maruyama R, Ushikoshi H, Esaki M, Kanamori H, Li L, Misao Y, Tezuka A, Toyo-Oka T, Minatoguchi S, Fujiwara T, Fujiwara H. Yamanaka N, Takahashi R, Okada H, Maruyama R, Misao K, Tsujita T, Takahashi T, Okada H.

"Fas-ten" your seat belt: anti-apoptotic anatomy in 72 cases. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol. 1978; 90: 57–70.

Kawase Y, Maruyama R, Okada H, Minatoguchi S, Fujiwara T, Fujiwara H. Pathol. Jpn. 1997; 272: 18542–5.

1998; 82: 1130–8. Circ Res. 2003; 92: 715–24.

134. Miyata S, Takemura G, Kawase Y, Li Y, Okada H, Maruyama R, Ushikoshi H, Esaki M, Kamamori H, Li L, Misao Y, Tezuka A, Toyo-Oka T, Minatoguchi S, Fujiwara T, Fujiwara H. Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. Am J Pathol. 2006; 168: 386-97.

Koseki T, Inohara N, Chen S, Nunez G, ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA. 1998; 95: 5156–60.

Srinivasula SM, Ahmad M, Oltitile S, Bullrich F, Banks S, Wang Y, Fernandes-Alnemri T, Croce CM, Litwack G, Tomasselli KJ, Armstrong RC, Alnemri ES. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem. 1997; 272: 18542–5.

Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–12.

Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300–4.